In this online CME self-learning program:
The use of androgen deprivation therapy for prostate cancer has greatly increased in the last 15 years because statistics have shown it has about a 25% better 10 year mortality outcome when compared to observation alone. It has been associated with reductions in morbidity and metastases and increased survival rates when combined with radiation both in more advanced stages of the disease and in disease confined to the prostate. Adjuvant aromatase inhibitor (AI) therapy is a common treatment in postmenopausal women with hormone receptor positive breast cancer. Bone fractures are of particular concern in these patents, given their association with increased mortality in prostate cancer and breast cancer patients. Studies have shown that about 19.4% of men who received androgen deprivation therapy experienced a fracture, and 5.2% of them required hospitalization.
Patients taking AIs or androgen deprivation therapy have benefited from vitamin D, calcium, and bisphosphonate therapy. Denosumab, used in patients receiving AIs has been shown to significantly increase lumbar spine BMD by 7.6% from baseline versus placebo.Increases were observed as early as 1 month from beginning of therapy and were not influenced by duration of AI therapy.Increases in BMD can also be seen in the hip, total body, and femoral neck.
Faculty introduction, disclosures
Introduction content: cursory refresher and review of oncology patients at high risk of bone fracture [Learning objective #1]
Treatment options [Learning objectives #2, 3, 4, & 5]
Summary, conclusions, and best practice recap
The following healthcare professionals: oncologists, primary care physicians, and endocrinologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology, endocrinology and internal medicine; and any other healthcare professionals who commonly care for patients with breast cancer or prostate cancer.
This program is supported by educational grants from AMGEN.
Release Date: November 17, 2017 -- Expiration Date: November 17, 2019
Faculty: Azeez Farooki, MD
By the end of the session the participant will be able to:
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Dr. Azeez Farooki, MD, Associate Clinical Member Endocrinology Service, Memorial Sloan Kettering Cancer Center, New York, New York has worked as a consultant for Amgen.
Disclosures of Peer Reviewer: Brooke Crawford, MD has no relevant financial disclosures.
Disclosures of Peer Reviewer: Eric Goldberg, MD has no relevant financial disclosures.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP has no relevant financial disclosures.
Commercial Support Disclosure: This program is supported by educational grants from AMGEN.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.